126 related articles for article (PubMed ID: 8550789)
1. RET mutation screening in sporadic pheochromocytoma.
Arnold A
J Clin Endocrinol Metab; 1996 Jan; 81(1):430. PubMed ID: 8550789
[No Abstract] [Full Text] [Related]
2. RET proto-oncogene mutations and rearrangements in endocrine diseases.
Lloyd RV
Am J Pathol; 1995 Dec; 147(6):1539-44. PubMed ID: 7495277
[No Abstract] [Full Text] [Related]
3. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2.
Ponder BA
Cancer Surv; 1995; 25():195-205. PubMed ID: 8718519
[No Abstract] [Full Text] [Related]
4. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
5. Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma.
Eng C; Foster KA; Healey CS; Houghton C; Gayther SA; Mulligan LM; Ponder BA
Br J Cancer; 1996 Aug; 74(3):339-41. PubMed ID: 8695346
[TBL] [Abstract][Full Text] [Related]
6. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.
Eng C; Smith DP; Mulligan LM; Nagai MA; Healey CS; Ponder MA; Gardner E; Scheumann GF; Jackson CE; Tunnacliffe A
Hum Mol Genet; 1994 Feb; 3(2):237-41. PubMed ID: 7911697
[TBL] [Abstract][Full Text] [Related]
7. The RET proto-oncogene in sporadic pheochromocytomas.
Takaya K; Yoshimasa T; Arai H; Tamura N; Miyamoto Y; Itoh H; Nakao K
Intern Med; 1996 Jun; 35(6):449-52. PubMed ID: 8835594
[TBL] [Abstract][Full Text] [Related]
8. Absence of RET proto-oncogene mutations in a father and son with pheochromocytoma and pancreatic islet cell tumor.
Kawasaki T; Tomita Y; Takahashi H; Takeda M; Tanaka H; Tamiya Y; Takahashi K
Int J Urol; 1997 Mar; 4(2):169-71. PubMed ID: 9179691
[TBL] [Abstract][Full Text] [Related]
9. The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects.
Beldjord C; Desclaux-Arramond F; Raffin-Sanson M; Corvol JC; De Keyzer Y; Luton JP; Plouin PF; Bertagna X
J Clin Endocrinol Metab; 1995 Jul; 80(7):2063-8. PubMed ID: 7608256
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the RET protooncogene in sporadic pheochromocytomas.
Lindor NM; Honchel R; Khosla S; Thibodeau SN
J Clin Endocrinol Metab; 1995 Feb; 80(2):627-9. PubMed ID: 7852530
[TBL] [Abstract][Full Text] [Related]
11. Sporadic pheochromocytomas are rarely associated with germline mutations in the vhl tumor suppressor gene or the ret protooncogene.
Brauch H; Hoeppner W; Jähnig H; Wöhl T; Engelhardt D; Spelsberg F; Ritter MM
J Clin Endocrinol Metab; 1997 Dec; 82(12):4101-4. PubMed ID: 9398721
[TBL] [Abstract][Full Text] [Related]
12. Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases.
Hofstra RM; Stelwagen T; Stulp RP; de Jong D; Hulsbeek M; Kamsteeg EJ; van den Berg A; Landsvater RM; Vermey A; Molenaar WM; Lips CJ; Buys CH
J Clin Endocrinol Metab; 1996 Aug; 81(8):2881-4. PubMed ID: 8768845
[TBL] [Abstract][Full Text] [Related]
13. Utility of RET mutation analysis in multiple endocrine neoplasia type 2.
Noll WW
Arch Pathol Lab Med; 1999 Nov; 123(11):1047-9. PubMed ID: 10539905
[TBL] [Abstract][Full Text] [Related]
14. Incidence and clinical relevance of RET proto-oncogene germline mutations in pheochromocytoma patients.
Januszewicz A; Neumann HP; Loń I; Szmigielski C; Symonides B; Kabat M; Apel TW; Wocial B; Lapiński M; Januszewicz W
J Hypertens; 2000 Aug; 18(8):1019-23. PubMed ID: 10953992
[TBL] [Abstract][Full Text] [Related]
15. Sporadic multiple endocrine neoplasia type 2A.
Yamashita S
Intern Med; 1999 Feb; 38(2):80. PubMed ID: 10225659
[No Abstract] [Full Text] [Related]
16. First continuous human pheochromocytoma cell line: KNA. Biological, cytogenetic and molecular characterization of KNA cells.
Pfragner R; Behmel A; Smith DP; Ponder BA; Wirnsberger G; Rinner I; Porta S; Henn T; Niederle B
J Neurocytol; 1998 Mar; 27(3):175-86. PubMed ID: 10640177
[TBL] [Abstract][Full Text] [Related]
17. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas.
Santoro M; Rosati R; Grieco M; Berlingieri MT; D'Amato GL; de Franciscis V; Fusco A
Oncogene; 1990 Oct; 5(10):1595-8. PubMed ID: 1701232
[TBL] [Abstract][Full Text] [Related]
18. Expression of the ret proto-oncogene in human medullary thyroid carcinomas and pheochromocytomas of MEN 2A.
Miya A; Yamamoto M; Morimoto H; Tanaka N; Shin E; Karakawa K; Toyoshima K; Ishizaka Y; Mori T; Takai S
Henry Ford Hosp Med J; 1992; 40(3-4):215-9. PubMed ID: 1362408
[TBL] [Abstract][Full Text] [Related]
19. Occurrence of pheochromocytoma in a MEN2A family with codon 609 mutation of the RET proto-oncogene.
Igaz P; Patócs A; Rácz K; Klein I; Váradi A; Esik O
J Clin Endocrinol Metab; 2002 Jun; 87(6):2994. PubMed ID: 12050290
[No Abstract] [Full Text] [Related]
20. Expression of the ret proto-oncogene in phaeochromocytoma. An in situ hybridization and northern blot study.
Matias-Guiu X; Colomer A; Mato E; Cuatrecasas M; Komminoth P; Prat J; Wolfe H
J Pathol; 1995 May; 176(1):63-8. PubMed ID: 7616358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
